Pfizer lung cancer drug promising in early tests

June 5, 2010 By MARILYNN MARCHIONE , AP Medical Writer

(AP) -- It's way too soon to declare success, but an experimental drug for lung cancer patients with a certain gene showed extraordinary promise in early testing, doctors reported at a cancer conference on Saturday.

More than 90 percent of the 82 patients in a study saw their tumors shrink after two months on the drug, Pfizer Inc.'s crizotinib, (crih-ZAH-tin-ib), researchers reported.

Doctors had expected only about 10 percent of these very sick patients to respond to the drug, according to one of the study's leaders, Dr. Yung-Jue Bang of the Seoul National University College of Medicine in South Korea.

These were people with advanced disease, including some whose cancers had spread to the brain. They had already tried an average of three other drugs. Responses to crizotinib have lasted up to 15 months so far, and the drug has been rushed into late-stage testing, Bang said.

Many leading cancer specialists, who normally don't get excited until a drug proves effective in large studies against existing treatments, said the research so far on crizotinib was promising.

"It's early, but I'm impressed by it. It looks extremely effective," said Dr. Roy Herbst, chief at the University of Texas M.D. Anderson Cancer Center in Houston. He has consulted for makers of other lung but not this one.

Dr. Alice Shaw, the Massachusetts General Hospital doctor who is leading a larger study of crizotinib, agreed.

"I don't think there is false hope. The data are so strong," she said.

The drug targets a gene that promotes tumor growth and is found in about 4 percent of lung cancers, especially among younger, non-smokers. This small percentage is still a lot of people: nearly 220,000 new cases of lung cancer are diagnosed each year in the United States alone, and it is the world's top cancer killer.

That means that up to 10,000 people in the U.S. annually could benefit, said Dr. Mark Kris, a lung cancer specialist at Memorial Sloan-Kettering Cancer Center in New York, who has consulted for Pfizer.

Two other gene-targeted treatments, Tarceva and Iressa, help about 20,000 lung cancer patients annually in the U.S.

"We're chipping away at large numbers of patients," and future gene discoveries should add to the number helped, Herbst said.

The gene targeted by crizotinib was discovered in 2007, Kris noted.

"Once we understand a cancer cell, we can come up with a treatment very quickly," he said.

No show-stopping side effects were seen in the first study - half of patients on crizotinib had diarrhea, nausea or vomiting - but much larger tests are needed to establish safety.

Even more testing is needed to see if the drug is more effective than existing treatments, how long any benefits last, and whether it improves survival - not just shrinks tumors.

sponsored the study and has already launched bigger studies to compare crizotinib to current standard treatments. The company hopes to seek federal Food and Drug Administration approval for the drug next year.

The study was presented Saturday at a meeting in Chicago of the American Society of Clinical Oncology.

More information: Cancer meeting: http://www.asco.org
National Cancer Institute: http://www.cancer.gov
Pfizer: http://www.pfizer.com

shares

Related Stories

Recommended for you

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.